|

oxaliplatin+capecitabine+bevacizumab+PD-1 antibody Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Chinese PLA General Hospital1

Indications

  • Microsatellite Stable Colorectal Carcinoma1
  • RAS Mutation1
  • Colorectal Neoplasms1
  • Colorectal Cancer1
  • Cancer1

Other1 trial

PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.